<DOC>
	<DOCNO>NCT02047006</DOCNO>
	<brief_summary>Rivaroxaban recently develop factor Xa ( FXa ) inhibitor prevention treatment thromboembolic disease . There data dose adjustment patient severe chronic renal failure . It 's use therefore recommend patient population . The present study aim asses 12 hemodialysis patient require prevention deep vein thrombosis : 1. AUC Cmax 10 mg rivaroxaban 2. effect 10 mg rivaroxaban coagulation assay 3. effect single dialysis session plasma level rivaroxaban anti-Xa level 4. safety tolerability rivaroxaban</brief_summary>
	<brief_title>Dose-finding Rivaroxaban Hemodialysis</brief_title>
	<detailed_description>1 . Background Rationale : Vitamin K antagonists standard anticoagulant treatment decade , despite unpredictable pharmacology slow onset offset action , require frequent monitor bridge low molecular weight heparin ( LMWH ) , result substantial risk under- overtreatment . Patients end-stage renal disease increase risk bleeding due underlying disease . Therefore , anticoagulant need use caution patient . In addition , vitamin K antagonists increasingly implicate development vascular calcification already vulnerable population . A search alternative anticoagulant therefore warrant . Rivaroxaban recently develop factor Xa ( FXa ) inhibitor prevention treatment thromboembolic disease ( 1 ) . Rivaroxaban much low pharmacokinetic variability little interaction food drug , contribute consistent predictable anticoagulation . As consequence , routine monitoring require . Rivaroxaban show effective safe large trial prevention treatment venous thromboembolism ( 2,3 ) prevention stroke atrial fibrillation ( 4 ) . Rivaroxaban inhibits factor Xa concentration-dependent manner . Even though routine monitoring require , clinical situation evaluation anticoagulant effect desirable . Rivaroxaban prolongs prothrombin time ( PT ) activate partial thromboplastin time ( aPTTT ) concentration-dependent manner . However , extent prolongation varies considerably type reagent use . This variation reduce conversion PT value give second international normalized ratio value ; therefore , PT activate partial thromboplastin time useful measure pharmacodynamic effect rivaroxaban . Anti- Factor Xa activity also influence rivaroxaban reliable method evaluate clinical effect rivaroxaban ( 5 ) . The absolute bioavailability rivaroxaban high ( 80 % - 100 % ) 10 mg dose , maximum plasma concentration ( Cmax ) . appear 2 - 4 hour tablet intake . Intake food affect rivaroxaban area curve ( AUC ) Cmax . Rivaroxaban pharmacokinetics approximately linear 15 mg daily . Plasma protein bind human high approximately 92 % 95 % , serum albumin main binding component . Due high plasma protein bind rivaroxaban expect dialysable . There , however , data plasma protein bind hemodialysis patient . Unchanged rivaroxaban important compound human plasma , major active circulate metabolite present . With systemic clearance 10 l/h , rivaroxaban classify low-clearance drug . After intravenous administration 1 mg dose elimination half-life 4.5 hour . After oral administration 10 mg dose elimination become absorption rate limit mean terminal half-lives 7 11 hour ( 6,7 ) . Rivaroxaban dual mode elimination . Approximately 2/3 administer dose metabolized inactive metabolite liver , half eliminate renally half eliminated faecal route . The final 1/3 administer dose undergoes direct renal excretion unchanged active substance urine , mainly via active renal secretion ( 6,7 ) . In individual mild ( measure creatinine clearance [ CreaCl ] 50-80 ml/min ) , moderate ( CreaCl 30-49 ml/min ) severe ( CreaCl 15-29 ml/min ) renal impairment , rivaroxaban plasma concentration ( AUC ) increase 1.4- , 1.5- 1.6-fold respectively , compare control subject , whereas maximum plasma concentration relatively unaffected ( 8 ) . Corresponding increase pharmacodynamic effect pronounce . In individual mild , moderate severe renal impairment overall inhibition factor Xa-activity increase factor 1.5 , 1.9 2.0 respectively , compare healthy volunteer ; prolongation PT similarly increase factor 1.3 , 2.2 2.4 respectively ( 8 ) . There data patient CreaCl &lt; 15 ml/min . Based data , dose guideline patient renal failure issue . No dose adjustment necessary patient mild renal impairment ( CreaCl 50-80 ml/min ) moderate renal impairment ( CreaCl 30-49 ml/min ) . In patient severe renal impairment ( CreaCl 15-29 ml/min ) , rivaroxaban use caution . Use recommend patient CreaCl &lt; 15 ml/min ( 6,7 ) . 2 . Study design A two-centre , non-blinded cohort study . 3 . Study objectives 1 ) To measure AUC Cmax 10 mg rivaroxaban hemodialysis patient 2 ) To assess effect 10 mg rivaroxaban coagulation assay hemodialysis patient : - anti-Xa assay - prothrombin assay 3 ) To assess effect single dialysis session plasma level rivaroxaban anti-Xa level 4 ) To assess safety tolerability rivaroxaban hemodialysis patient 4 . Study subject 1 . Enrolment procedure The study protocol discuss eligible patient . All patient treatment participate center meet in- exclusion criterion give inform consent include . 2 . Planned number participant 12 patient 3 . Inclusion criterion - age ≥18 year - sign informed consent - chronic hemodialysis patient without immediate life-threatening condition , dialyse three time week least three month - require anticoagulation prevention deep venous thrombosis 4 . Exclusion criterion - residual renal function , define residual diuresis &gt; 50 ml/day - know intestinal malabsorption - inability take oral medication - mechanical heart valve - inability stop co-medication cause major interaction rivaroxaban ( e.g . ketoconazole , itraconazole , voriconazole , posaconazole , ritonavir ) - severe liver dysfunction Child-Pugh grade C</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>age ≥18 year sign informed consent chronic hemodialysis patient without immediate lifethreatening condition , dialyse three time week least three month require anticoagulation prevention deep venous thrombosis residual renal function , define residual diuresis &gt; 50 ml/day know intestinal malabsorption inability take oral medication mechanical heart valve inability stop comedication cause major interaction rivaroxaban ( e.g . ketoconazole , itraconazole , voriconazole , posaconazole , ritonavir ) severe liver dysfunction ChildPugh grade C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Hemodialysis</keyword>
	<keyword>Rivaroxaban</keyword>
	<keyword>AUC</keyword>
</DOC>